drugset / Trial / NCT05305222
A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab
RandomizedParallel-groupQuadruple-blindBasic science
Summary
The main objective of this study is to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single intravenous (IV) infusion of risankizumab in healthy Japanese and Caucasian participants.
Timeline
- Start
- 2017-10-23
- Primary completion
- 2018-06-15
- Completion
- 2018-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risankizumab | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.